Ligand Pharmaceuticals Incorporated (LGND) - What Are Brokerages Thinking About This Stock?

Ligand Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Broker sentiment is broadly positive: Nine analysts give Ligand Pharmaceuticals a “Moderate Buy” consensus—eight buy ratings and one hold—with an average 12-month price target of $355.38.
  • Quarterly results beat estimates: EPS of $2.67 and revenue of $78.75 million topped forecasts, but revenue fell 31.8% year over year.
  • Insiders have been selling shares: Company insiders sold 24,093 shares worth about $7.38 million over the past 90 days; institutional investors own 91.28% of the stock.
  • Five stocks to consider instead of Ligand Pharmaceuticals.

Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $355.38.

A number of equities research analysts have weighed in on LGND shares. Royal Bank Of Canada lifted their price objective on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the company an "outperform" rating in a report on Friday, October 30th. Leerink Partners assumed coverage on Ligand Pharmaceuticals in a research report on Friday, August 14th. They set an "outperform" rating and a $330.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $358.00 target price on shares of Ligand Pharmaceuticals in a research note on Thursday, September 24th. Weiss Ratings cut Ligand Pharmaceuticals from a "buy (b)" rating to a "hold (c)" rating in a report on Monday, November 2nd. Finally, Citigroup raised their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a "buy" rating in a report on Thursday, November 5th.

Get Our Latest Report on Ligand Pharmaceuticals

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 5,000 shares of the firm's stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $304.07, for a total value of $1,520,350.00. Following the completion of the sale, the insider owned 31,854 shares of the company's stock, valued at approximately $9,685,845.78. This trade represents a 13.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Martine Zimmermann sold 2,000 shares of the business's stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $318.17, for a total transaction of $636,340.00. Following the sale, the director owned 1,782 shares in the company, valued at $566,978.94. The trade was a 52.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 24,093 shares of company stock worth $7,384,287. Insiders own 5.60% of the company's stock.

Hedge Funds Weigh In On Ligand Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Ranger Investment Management L.P. purchased a new stake in Ligand Pharmaceuticals in the 2nd quarter worth approximately $81,424,000. Bank of New York Mellon Corp purchased a new position in shares of Ligand Pharmaceuticals during the 2nd quarter worth $41,429,000. William Blair Investment Management LLC purchased a new position in shares of Ligand Pharmaceuticals during the 3rd quarter worth $37,264,000. Russell Investments Group Ltd. lifted its stake in shares of Ligand Pharmaceuticals by 41.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 170,089 shares of the biotechnology company's stock worth $53,131,000 after purchasing an additional 49,785 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Ligand Pharmaceuticals by 14.6% during the third quarter. Goldman Sachs Group Inc. now owns 370,529 shares of the biotechnology company's stock worth $115,742,000 after purchasing an additional 47,284 shares during the last quarter. Hedge funds and other institutional investors own 91.28% of the company's stock.

Ligand Pharmaceuticals Stock Down 2.3%

LGND stock opened at $301.71 on Tuesday. Ligand Pharmaceuticals has a one year low of $175.89 and a one year high of $326.63. The stock has a market capitalization of $6.03 billion, a PE ratio of 134.69, a price-to-earnings-growth ratio of 5.52 and a beta of 1.16. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.19 and a current ratio of 1.22. The company has a fifty day moving average of $302.03 and a 200-day moving average of $258.58.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.33 by $0.34. The business had revenue of $78.75 million for the quarter, compared to analyst estimates of $77.00 million. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The business's revenue was down 31.8% compared to the same quarter last year. During the same period in the previous year, the business posted $3.09 earnings per share. As a group, analysts expect that Ligand Pharmaceuticals will post 2.35 EPS for the current year.

Ligand Pharmaceuticals Company Profile

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Further Reading

Analyst Recommendations for Ligand Pharmaceuticals (NASDAQ:LGND)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?

Before you consider Ligand Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.

While Ligand Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines